NexEos Bio

NexEos Bio Announces Positive Results from Clinical Study Evaluating NTX-1024 in Patients with Vernal Keratoconjunctivitis

The NexEos Bio management team, together with collaborators at The University of Utah, are highly-seasoned biopharmaceutical professionals with several decades of experience in both the field of eosinophil research and pharmaceutical development and commercialization.

NexEos Bio is a privately held medical diagnostics company dedicated to improving the detection, diagnosis, treatment and life-long management of patients living with chronic, eosinophil-related inflammatory diseases.

The NexEos Bio lead program (NDX33-o) is a novel, non-invasive imaging agent for the diagnosis, treatment monitoring, and management of Eosinophilic Esophagitis (EoE).

NexEos Bio receives FDA approval to advance its investigational drug into Phase II/III trials for treating vernal keratoconjunctivitis, a chronic eye condition. The company, based in Malvern, Pennsylvania, submitted an investigational new drug (IND) application to proceed with human testing. The trial marks a critical step in evaluating the safety and efficacy of the candidate therapy for patients with this inflammatory eye disorder.

Feb 2026market-scope.comNews article

NexEos Bio receives FDA clearance for its investigational new drug application for NTX-1024, an ophthalmic solution targeting vernal keratoconjunctivitis. The company plans to initiate a phase 2/3 randomized, double-masked clinical trial later this year to evaluate the safety and efficacy of the eye drop treatment.

Feb 2026healio.comNews article

NexEos Bio secures US FDA Investigational New Drug (IND) clearance for its experimental therapy **NTX-1024**, enabling progression into a Phase II/III clinical trial. The drug targets **vernal keratoconjunctivitis**, a chronic eye inflammation disorder. This milestone follows regulatory approval to test NTX-1024’s safety and efficacy in human subjects.

Feb 2026PharmaShotsNews article

NexEos Bio receives FDA clearance to advance **NTX-1024**, its investigational therapy, into a **Phase II/III clinical trial** for treating **vernal keratoconjunctivitis (VKC)**, a rare inflammatory eye disease. The company specializes in eosinophil-mediated disease therapies. The trial will evaluate NTX-1024’s safety and efficacy in patients with VKC.

Feb 2026BioSpaceNews article